GeneDx Cuts Full-Year Revenue Guidance by Over 12%, Reports Q1 Adjusted Net Loss

summarizeSummary

GeneDx Holdings Corp. reported first-quarter results with a significant year-over-year increase in exome and genome testing volume, but lowered its full-year 2026 revenue guidance by over 12% and reported an adjusted net loss for the quarter.

check_boxKey Events

• Q1 Financial Performance

  Revenue grew 17% year-over-year to $102.3 million, driven by a 34% increase in exome and genome test volume. However, the company reported an adjusted net loss of $8.2 million, a decline from an adjusted net income of $9.2 million in Q1 2025.

• Significant Guidance Reduction

  Full-year 2026 revenue guidance was lowered to $475-$490 million from the previous $540-$555 million, representing a cut of over 12%. Exome and genome revenue growth guidance was also reduced.

• Shift to Adjusted Net Loss Outlook

  The company now expects an adjusted net loss of approximately $5 million for Q2 2026, indicating a more challenging profitability outlook in the near term.

• Impairment Loss

  GAAP net loss for Q1 2026 included a $31.3 million impairment loss.

auto_awesomeAnalysis

This 8-K filing contains highly negative news for GeneDx investors, primarily due to the substantial reduction in full-year revenue guidance. The company's updated outlook now projects revenue to be over 12% lower than previously expected, signaling a significant slowdown or increased headwinds. The shift from an adjusted net income in the prior year to an adjusted net loss in Q1 2026, coupled with a projected adjusted net loss for Q2, raises concerns about the company's path to profitability despite strong volume growth in its core exome and genome testing. The $31.3 million impairment loss further contributes to the GAAP net loss. Investors will likely react negatively to the revised outlook, especially given the stock is already trading near its 52-week low. The company's ability to manage its cash burn and achieve its revised profitability targets will be critical to monitor.